Recent Advances in Progresses and Prospects of IL-37 in Central Nervous System Diseases

Li, Xinrui; Yan, Bing; Du, Jingshan S.; Xu, Shanshan; Liu, Lu; Pan, Cai-Fei; Kang, Xianhui; Zhu, Shengmei

doi:10.3390/brainsci12060723

Cited by 3 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interleukin (IL) 1F7, also known as IL-37, has an important anti-inflammatory and immunosuppressive effect. Systemic alterations of IL-1F7 have been described in cancer ( 58 ), central nervous system disorders ( 59 ) and other autoimmune and inflammatory diseases ( 60 ). Although IL-1F7 has an effective effect on pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β ( 61 ), our results showed that IL-1F7 did not change at any of the time points analyzed and showed no correlation with other inflammatory cytokines.…”

Section: Discussionmentioning

confidence: 99%

The inflammatory and metabolic status of patients with sudden-onset sensorineural hearing loss

do Amaral,

Peron,

Soeiro

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

IntroductionSudden sensorineural hearing loss (SSNHL) is a common emergency symptom in otolaryngology that requires immediate diagnosis and treatment. SSNHL has a multifactorial etiology, and its pathophysiologic mechanisms may be associated with inflammatory and metabolic changes that may affect the cochlear microenvironment or its nervous component, thus triggering the process or hindering hearing recovery. Therefore, the aim of this study was to assess metabolic and inflammatory changes to identify systemic parameters that could serve as prognostic factors for hearing recovery in patients with SSNHL.Materials and methodsThirty patients with a sudden hearing loss of at least 30 dB in three contiguous frequencies were enrolled in this study. Patients were followed up for 4 months and peripheral blood samples were collected at 7 days (V1), 30 days (V2) and 120 days (V3). Interleukins (IL)-1F7, IL-2, IL-4, IL-5, IL-6, IL-10, interferon γ (IFN-γ), tumor necrosis factor α (TNF-α) and adiponectin were quantified in serum. In addition, lipid and glycemic profiles as well as concentration of creatinine, uric acid, fructosamine, peroxide, total proteins and albumin were analyzed. Patients underwent weekly ear-specific hearing tests with standard pure tone thresholds for frequencies of 250–8,000 Hz, speech recognition threshold and word recognition score.ResultsPatients with SSNHL were divided into a group of patients who did not achieve hearing recovery (n = 14) and another group who achieved complete and significant recovery (n = 16). Most serologic parameters showed no significant changes or values indicating clinical changes. However, IFN-γ levels decreased by 36.3% between V1 and V2. The cytokine TNF-α showed a statistically significant decrease from V1 to V3 (from 22.91 to 10.34 pg./mL). Adiponectin showed a decrease from 553.7 ng/mL in V1 to 454.4 ng/mL in V3.DiscussionOur results show that serologic cytokine levels change in the acute phase of manifestation of SSNHL and establish a parallel between systemic changes and improvements in hearing, especially TNF-α, which showed differences in hearing recovery. The use of IFN-γ, TNF-α and adiponectin may elucidate the clinical improvement in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The inflammatory and metabolic status of patients with sudden-onset sensorineural hearing loss

do Amaral,

Peron,

Soeiro

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…In turn, clinical research studies indicate the emerging role of the anti-inflammatory cytokine IL-37 in common CNS diseases. Although IL-37 has been previously associated with the pathogenesis of autoimmune diseases and cancer, the present review by Li et al focuses on the mechanism of action of IL-37 in CNS and the inhibition of inflammatory cytokines, such as IL-1β, IL-6, and tumor necrosis factor-α (TNF-α), indicating therapeutic potential [ 2 ].…”

mentioning

confidence: 99%

New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders

2022

View full text Add to dashboard Cite

show abstract

Neurovascular unit, neuroinflammation and neurodegeneration markers in brain disorders

Kempuraj,

Dourvetakis,

Cohen

et al. 2024

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Neurovascular unit (NVU) inflammation via activation of glial cells and neuronal damage plays a critical role in neurodegenerative diseases. Though the exact mechanism of disease pathogenesis is not understood, certain biomarkers provide valuable insight into the disease pathogenesis, severity, progression and therapeutic efficacy. These markers can be used to assess pathophysiological status of brain cells including neurons, astrocytes, microglia, oligodendrocytes, specialized microvascular endothelial cells, pericytes, NVU, and blood-brain barrier (BBB) disruption. Damage or derangements in tight junction (TJ), adherens junction (AdJ), and gap junction (GJ) components of the BBB lead to increased permeability and neuroinflammation in various brain disorders including neurodegenerative disorders. Thus, neuroinflammatory markers can be evaluated in blood, cerebrospinal fluid (CSF), or brain tissues to determine neurological disease severity, progression, and therapeutic responsiveness. Chronic inflammation is common in age-related neurodegenerative disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), and dementia. Neurotrauma/traumatic brain injury (TBI) also leads to acute and chronic neuroinflammatory responses. The expression of some markers may also be altered many years or even decades before the onset of neurodegenerative disorders. In this review, we discuss markers of neuroinflammation, and neurodegeneration associated with acute and chronic brain disorders, especially those associated with neurovascular pathologies. These biomarkers can be evaluated in CSF, or brain tissues. Neurofilament light (NfL), ubiquitin C-terminal hydrolase-L1 (UCHL1), glial fibrillary acidic protein (GFAP), Ionized calcium-binding adaptor molecule 1 (Iba-1), transmembrane protein 119 (TMEM119), aquaporin, endothelin-1, and platelet-derived growth factor receptor beta (PDGFRβ) are some important neuroinflammatory markers. Recent BBB-on-a-chip modeling offers promising potential for providing an in-depth understanding of brain disorders and neurotherapeutics. Integration of these markers in clinical practice could potentially enhance early diagnosis, monitor disease progression, and improve therapeutic outcomes.

show abstract

Recent Advances in Progresses and Prospects of IL-37 in Central Nervous System Diseases

Cited by 3 publications

References 95 publications

The inflammatory and metabolic status of patients with sudden-onset sensorineural hearing loss

The inflammatory and metabolic status of patients with sudden-onset sensorineural hearing loss

New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders

Neurovascular unit, neuroinflammation and neurodegeneration markers in brain disorders

Contact Info

Product

Resources

About